These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29729689)

  • 41. Transforming growth factor-alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice.
    Moore AB; He H; Yoshida A; Rico PJ; Haseman JK; Dixon D
    Exp Toxicol Pathol; 2000 Jun; 52(3):195-200. PubMed ID: 10930119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.
    Croce S; Ribeiro A; Brulard C; Noel JC; Amant F; Stoeckle E; Devouassoux-Shisheborah M; Floquet A; Arnould L; Guyon F; Mishellany F; Garbay D; Cuppens T; Zikan M; Leroux A; Frouin E; Duvillard P; Terrier P; Farre I; Valo I; MacGrogan GM; Chibon F
    Mod Pathol; 2015 Jul; 28(7):1001-10. PubMed ID: 25932961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors.
    Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX
    Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
    Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
    Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
    Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
    Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
    Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
    Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
    Chen L; Yang B
    Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
    Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
    Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
    Ip PP; Cheung AN; Clement PB
    Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
    Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
    Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intraoperative Frozen Section Biopsy of Uterine Smooth Muscle Tumors: A Clinicopathologic Analysis of 112 Cases With Emphasis on Potential Diagnostic Pitfalls.
    Lok J; Tse KY; Lee EYP; Wong RWC; Cheng ISY; Chan ANH; Leung CKL; Cheung ANY; Ip PPC
    Am J Surg Pathol; 2021 Sep; 45(9):1179-1189. PubMed ID: 34074809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Criteria for risk stratification of vulvar and vaginal smooth muscle tumors: a follow-up study with application to leiomyoma variants, smooth muscle tumors of uncertain malignant potential, and leiomyosarcomas.
    Swanson AA; Howitt BE; Schoolmeester JK
    Hum Pathol; 2020 Sep; 103():83-94. PubMed ID: 32687944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis.
    Cao HY; Yang S; Wang S; Deng LY; Lou JY
    Genet Mol Res; 2017 Mar; 16(1):. PubMed ID: 28340268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings.
    Tanaka YO; Nishida M; Tsunoda H; Okamoto Y; Yoshikawa H
    J Magn Reson Imaging; 2004 Dec; 20(6):998-1007. PubMed ID: 15558559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.
    Kelley TW; Borden EC; Goldblum JR
    Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):338-41. PubMed ID: 15536333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leiomyoma and Leiomyosarcoma (Primary and Metastatic) of the Oral and Maxillofacial Region: A Clinicopathological and Immunohistochemical Study of 27 Cases.
    de Araújo GR; Costa SFDS; Mesquita RA; Gomez RS; Dos Santos JN; Pontes HAR; de Andrade BAB; Romañach MJ; Agostini M; Vargas PA; de Cáceres CVBL; Santos-Silva AR; Ribeiro ACP; Brandão TB; Tomasi RA; Ferreyra RS; de Almeida OP; Fonseca FP
    Head Neck Pathol; 2022 Mar; 16(1):294-303. PubMed ID: 34106410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uterine smooth muscle tumours with hyperintense area on T
    Ando T; Kato H; Furui T; Morishige KI; Goshima S; Matsuo M
    Br J Radiol; 2018 Apr; 91(1084):20170767. PubMed ID: 29308922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.
    Fadare O; Liang SX
    Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.